Eli Lilly, the global pharmaceutical company, has announced the launch of Copellor® (Ixekizumab) in India, a drug designed to provide relief to adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Copellor® (Ixekizumab) is a humanized IgG4 monoclonal antibody that targets the IL-17A protein responsible for inflammation in psoriasis. The Drug Controller General of India (DCGI) has approved the drug, which is available in a single-dose prefilled autoinjector of 80mg/ml strength.
According to global studies, psoriasis has a significant impact on the quality of life of patients and is comparable to serious diseases like cancer and heart failure. By launching Copellor® (Ixekizumab) in India, Eli Lilly is offering healthcare providers a new treatment option for adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis, a major unmet need in the country. Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, stated that the launch of Copellor® (Ixekizumab) reinforces Lilly’s promise of bringing innovative medicines to India.
It is, however, recommended that Copellor® (Ixekizumab) be used only on the advice of a dermatologist or rheumatologist and under medical supervision. Eli Lilly’s introduction of Copellor® (Ixekizumab) in India is evidence of the company’s commitment to enhancing patient outcomes and quality of life by providing innovative treatments. The launch of Copellor® (Ixekizumab) demonstrates Eli Lilly’s dedication to providing effective treatment options and improving the lives of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis in India.
In conclusion, Eli Lilly’s Copellor® (Ixekizumab) launch in India is a significant step towards improving the quality of life for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. With the introduction of Copellor® (Ixekizumab) to the Indian market, healthcare providers can now offer patients an alternative treatment option to alleviate the impact of psoriasis and psoriatic arthritis